Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice
| Filename | 273. Zanichelli et al., Long-term Icatibant,Allergy 2017.pdf |
| Filesize | 117.18 KB |
| Version | o.273 |
| Date added | July 30, 2020 |
| Downloaded | 0 times |
| Category | Original Work |
| Tags | angioedema, Icatibant, real-world, Safety |
| Authors | Zanichelli, A., Maurer, M. Aberer, W., Caballero, T., Longhurst, H., Bouillet, L., Fabien, V., and Andresen, I. |
| Citation | Zanichelli, A., Maurer, M. Aberer, W., Caballero, T., Longhurst, H., Bouillet, L., Fabien, V., and Andresen, I.: Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. Allergy 2017: 72; 994-998. |
| Corresponding authors | Zanichelli, A |
| DocNum | o.273 |
| DocType | |
| Edition; Page | 72; 994-998 |
| IF | 6.05 |
| Publisher | Allergy |
| ReleaseDate | 2017 |
The Icatibant Outcome Survey (IOS) is an observational study monitoring safetyand effectiveness of icatibant in the real-world setting. We analyzed safety datafrom 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009and February 2015). Icatibant was generally well tolerated. Excluding off-labeluse and pregnancy, 438 patients (78.6%) did not report adverse events (AEs).The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinaldisorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icati-bant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in59 (10.6%) patients; only three events (drug inefficacy, gastritis, and refluxesophagitis) in two patients were considered related to icatibant. Notably, noSAEs related to icatibant occurred in patients with cardiovascular disease, nor inthose using icatibant at a frequency above label guidelines. Additionally, nomajor differences were noted in AEs occurring in on-labelvsoff-label icatibantusers.
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.